Apr 28, 2023 / 12:30PM GMT
Operator
Good day, and thank you for standing by. Welcome to the Tempest Therapeutics conference call. (Operator Instructions)
Please be advised that today's conference is being recorded.
I would now like to hand the conference over to your speaker today, Nicholas Maestas, Vice President of Finance and Strategy. Please go ahead.
Nicholas Maestas - Tempest Therapeutics, Inc. - VP, Strategy & Finance
Thank you, operator, and good morning, everyone. Thank you for joining our call to discuss the positive early data from the global randomized trial of TPST-1120 in first-line liver cancer. For your reference, the press release covering the news is available on the company's website at tempesttx.com.
Joining me on the call today are Steve Brady, Chief Executive Officer; Tom Dubensky, President; and Sam Whiting, Chief Medical Officer. As set forth on slide 2, during this call, we will be making forward-looking statements that are subject to risks and uncertainties. Our actual results may differ materially from those described. We encourage you to
Tempest Therapeutics Inc To Discuss Phase 1b/2 Combination Study of TPST-1120 in First-Line HCC Data Call Transcript
Apr 28, 2023
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers